Address

MaRS Center, South Tower

101 College Street, Suite 300

Toronto, ON, M5G 1L7


Get in touch

Keeping Patients in Sight

We see new ways to deliver drugs

Ripple is a clinical stage ophthalmic therapeutics company focused on sustained drug delivery without the use of polymers. Our platform prodrug technology generates composition of matter IP.  These novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower costs for payors.


Ripple’s Discovery

Epidel™ is founded on a discovery that drugs can be designed to deliver themselves without the need for polymers. Epidel™ prodrug materials are readily manufactured into implantable forms like cylinders and microspheres. Drug dissolves from the surface of the implant via surface erosion in a highly predictable manner: dose is dictated by implant surface area; duration by implant diameter. The result is an ability to finely tune pharmacokinetics to meet the needs of a target indication with precision control of drug dosing without the bulk added by a polymer.


In the true spirit of invention, Epidel was borne out of constraint. In the mid-1990s, the Controlled Release Field was focused on conjugating drugs into polymer backbones as a way of controlling drug release. While the science was conceptually appealing, the lack of reproducible manufacturing and the complexity of a polydisperse polymeric breakdown profile limited the translation into approval products.  


In our Toronto laboratories, these constraints inspired a minimalistic approach to re-think how controlled drug delivery could be achieved. A novel prodrug approach was discovered which provided a simple, highly predictable, and tunable way to achieve sustained drug release without the use of polymers or excipients. Read more.

Our Science

No polymers. BROAD PLATFORM APPLICATIONS.


  • High drug loading (80%+)
  • Smaller implants, no pro-inflammatory degradation products
  • Highly tunable drug release and duration via surface erosion
  • Simple, scalable, low cost manufacturing processes


Pulled Fiber

Microparticles by emulsion

Extruded Rod

Electro sprayed

Micro particles

Medical Device Coating

Solvent Casting

Powder Coating


Validating the vision timeline


2017 - 2019

Discover prodrugs can be engineered into implants without polymers. Establish focus in ophthalmology. Preclinical data confirms safety, efficacy and duration of Dex IVT implant.


2020

Ripple spun out of IBI; $10M (seed capital + convertible debt) Licensing Agreement signed with TOI; $15M Series A Financing.



2021

First Retina patients with RVO and DME treated in Ripple-1 with Dex IVT implant; Key patents granted; Pipeline expansion into Glaucoma.



2022

Ripple-1 Clinical Trial demonstrates safety, efficacy and duration of Dex IVT implant; Glaucoma implant preclinical data confirms safety & efficacy.




2023

Glaucoma preclinical repeat dosing studies establish long term safety after a second implant is administered.



2024

Ripple announces strategic partner agreements with AbbVie and Glaukos. Expands pipeline to include Dry AMD/GA.


PartnersHIPS

In the Fall of 2024, Ripple Therapeutics announced two partnership agreements. 

 

The first is a collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple’s innovative drug delivery platform. Under terms of the agreement, Ripple leads preclinical development of RTC-620 and upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple received an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.

 

Additionally, Ripple announced evaluation and licensing agreements with Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of eye disease.


Contact us

In addition to working with a number of partners evaluating our extended-release prodrug technology with their APIs, we are pursuing the expansion of our proprietary pipeline.

About us

Our leadership team has experience in managing both small and large public and private companies through various stages of growth and financing strategies (venture capital, M&A transactions, IPOs, PIPEs). They successfully sold the surface modification business of Interface Biologics to Evonik (ETR:EVK) in 2019 and founded Ripple Therapeutics in January of 2020.


Our team is made up of a high calibre group of PhD and MSc Chemists, Engineers and Material Scientists.

News & Updates

October 15, 2024
TORONTO, CANADA / ACCESSWIRE / October 15, 2024 - Ripple Therapeutics Corporation, a clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants, is pleased to announce evaluation and licensing agreements with Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal disease. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. The advantages of this technology include lower molecular weight and higher drug loading allowing for smaller implants and a lack of degradation products which provides both a clearer regulatory path as well as an improved safety profile. With an extended duration of therapeutic benefit, this technology will also reduce the treatment burden for patients. These agreements enable Glaukos to leverage Ripple’s proprietary technology platform to create sustained release implants of targeted APIs for both glaucoma and retinal diseases. If the program is successful, the evaluation agreement will automatically convert into a licensing agreement with future milestone payments and royalties. “We believe Ripple has one of the most promising drug delivery technologies currently under development,” commented Tomas Navratil, PhD, Chief Development Officer, Glaukos. “We are pleased with the progress of our collaboration and have enjoyed working with the Ripple team as we work together to bring these much-needed sustained release products to patients with critical unmet needs.” “This is the first of what we believe will be a number of transactions using our technology platform in concert with partners’ APIs to create sustained release implants which will benefit patients with extended duration and improved safety”, commented Tom Reeves, President & CEO, Ripple Therapeutics. “We look forward to continued collaboration with the entire Glaukos team.” About Ripple Therapeutics Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants. Ripple’s patented technology platform is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor both drug dose and duration. The advantages of this technology include lower molecular weight and higher drug loading allowing for smaller implants and a lack of degradation products which provides both a clearer regulatory path as well as an improved safety profile. With an extended duration of therapeutic benefit, this technology will also reduce the treatment burden for patients. www.rippletherapeutics.com Media Contact (Ripple) Julie Fotheringham, V.P. Marketing, People & Culture, Ripple Therapeutics M: 416-951-7988 E: jfotheringham@rippletherapeutics.com
September 23, 2024
Hemal Mehta, MBBS, MD (Cantab.), presented Efficacy and safety of the low dose dexamethasone IBE-814 IVT Implant for diabetic macular edema and retinal vein occlusion: Results of a first-in-human Phase 2 trial, at Euretina Congress in Barcelona, Spain, September 19-22, 2024. View Presentation
September 17, 2024
- Collaboration to leverage AbbVie's eye care expertise and Ripple’s innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma TORONTO, CANADA / ACCESSWIRE / September 17, 2024 / − Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple’s innovative drug delivery platform. Ripple’s patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing. “We’re pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics,” said Tom Reeves,President and Chief Executive Officer, Ripple Therapeutics. “By combining our drug delivery platform with AbbVie’s research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma.” Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options areneeded to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options. "At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies,” said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. “We are excited to partner with Ripple to further advance the development of RTC-620." Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales. About Ripple Therapeutics Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors. www.rippletherapeutics.com Piper Sandler acted as the exclusive financial advisor to Ripple. For further information: Media: Julie Fotheringham, jfotheringham@rippletherapeutics.com
Show More
Share by: